The estimated Net Worth of Tracie Oliver is at least $3.22 Million dollars as of 2 July 2024. Tracie Oliver owns over 9,394 units of Arrowhead Pharmaceuticals stock worth over $2,661,621 and over the last 2 years Tracie sold ARWR stock worth over $555,130.
Tracie has made over 3 trades of the Arrowhead Pharmaceuticals stock since 2023, according to the Form 4 filled with the SEC. Most recently Tracie sold 9,394 units of ARWR stock worth $237,480 on 2 July 2024.
The largest trade Tracie's ever made was selling 9,394 units of Arrowhead Pharmaceuticals stock on 2 July 2024 worth over $237,480. On average, Tracie trades about 4,598 units every 91 days since 2023. As of 2 July 2024 Tracie still owns at least 127,107 units of Arrowhead Pharmaceuticals stock.
You can see the complete history of Tracie Oliver stock trades at the bottom of the page.
Tracie's mailing address filed with the SEC is 177 E. COLORADO BLVD, SUITE 700, PASADENA, CA, 91105.
Over the last 21 years, insiders at Arrowhead Pharmaceuticals have traded over $129,489,075 worth of Arrowhead Pharmaceuticals stock and bought 176,205 units worth $991,784 . The most active insiders traders include David M Knott, Christopher Richard Anzalone und Kenneth Allen Myszkowski. On average, Arrowhead Pharmaceuticals executives and independent directors trade stock every 38 days with the average trade being worth of $868,068. The most recent stock trade was executed by Tracie Oliver on 2 July 2024, trading 9,394 units of ARWR stock currently worth $237,480.
arrowhead pharmaceuticals is a clinical stage, nasdaq listed (ticker arwr) company developing medicines that treat intractable diseases by silencing the genes that cause them. using a broad portfolio of rna chemistries and efficient modes of delivery, our therapies trigger the rna interference mechanism to induce rapid, deep and durable knockdown of target genes. rna interference, or rnai, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. our rnai-based therapeutics are at the leading edge of genetic-based therapy with the potential to bring life changing treatments for patients. our targeted rnai molecule (trimtm) platform utilizes ligand-mediated delivery and is designed to enable tissue-specific targeting while being structurally simple. the trim platform builds on more than a decade of work on actively targeted drug delivery and offers several advantages including simplified manufacturing
Arrowhead Pharmaceuticals executives and other stock owners filed with the SEC include: